• Shenzhen Neptunus Interlong flagged interim profit pressure, forecasting net profit attributable to owners of about RMB 7 million.
• That compares with RMB 19.07 million a year earlier, implying a drop of roughly 63%.
• Revenue expected to fall about 12% amid market conditions and policy impacts.
• Decline driven mainly by weaker sales in its medicines and medical devices manufacturing and sales segment.
• Interim results scheduled for release on Aug. 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281132), on August 12, 2026, and is solely responsible for the information contained therein.